Operaciones Ardelyx, Inc. - ARDX CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.0314 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Ardelyx Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 3.9194 |
| Abrir* | 3.8895 |
| Cambio de 1 año* | 471.99% |
| Rango del día* | 3.8895 - 3.9893 |
| Rango de 52 semanas | 0.49-5.13 |
| Volumen medio (10 días) | 4.09M |
| Volumen medio (3 meses) | 130.88M |
| Capitalización de mercado | 806.38M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 214.46M |
| Ingresos | 63.06M |
| EPS | -0.40 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 1.20 |
| Próxima fecha de resultados | Aug 2, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Jun 8, 2023 | 3.9194 | 0.1695 | 4.52% | 3.7499 | 3.9793 | 3.7199 |
| Jun 7, 2023 | 3.7299 | 0.0000 | 0.00% | 3.7299 | 3.7798 | 3.6501 |
| Jun 6, 2023 | 3.6900 | 0.0698 | 1.93% | 3.6202 | 3.7000 | 3.5803 |
| Jun 5, 2023 | 3.6003 | 0.1197 | 3.44% | 3.4806 | 3.6402 | 3.4507 |
| Jun 2, 2023 | 3.4906 | -0.0299 | -0.85% | 3.5205 | 3.5404 | 3.3908 |
| Jun 1, 2023 | 3.4806 | 0.2096 | 6.41% | 3.2710 | 3.5404 | 3.2213 |
| May 31, 2023 | 3.3011 | 0.0798 | 2.48% | 3.2213 | 3.3410 | 3.1814 |
| May 30, 2023 | 3.2213 | -0.0100 | -0.31% | 3.2313 | 3.4507 | 3.1714 |
| May 26, 2023 | 3.2612 | 0.0698 | 2.19% | 3.1914 | 3.3709 | 3.1814 |
| May 25, 2023 | 3.2811 | -0.2494 | -7.06% | 3.5305 | 3.5305 | 3.2213 |
| May 24, 2023 | 3.5105 | -0.0200 | -0.57% | 3.5305 | 3.5404 | 3.4207 |
| May 23, 2023 | 3.5504 | 0.0399 | 1.14% | 3.5105 | 3.7200 | 3.5105 |
| May 22, 2023 | 3.5404 | 0.0299 | 0.85% | 3.5105 | 3.6601 | 3.4806 |
| May 19, 2023 | 3.5305 | -0.1097 | -3.01% | 3.6402 | 3.7299 | 3.4008 |
| May 18, 2023 | 3.6202 | -0.3291 | -8.33% | 3.9493 | 4.0092 | 3.5404 |
| May 17, 2023 | 3.9095 | -0.2293 | -5.54% | 4.1388 | 4.1987 | 3.8396 |
| May 16, 2023 | 4.4480 | 0.0598 | 1.36% | 4.3882 | 4.4979 | 4.3084 |
| May 15, 2023 | 4.4480 | 0.1695 | 3.96% | 4.2785 | 4.6076 | 4.2585 |
| May 12, 2023 | 4.2885 | -0.0099 | -0.23% | 4.2984 | 4.3383 | 4.2386 |
| May 11, 2023 | 4.2785 | -0.0498 | -1.15% | 4.3283 | 4.4281 | 4.2286 |
Ardelyx, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Thursday, June 15, 2023 | ||
| Hora (UTC) (UTC) 12:30 | País US
| Evento Ardelyx Inc Annual Shareholders Meeting Ardelyx Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 2, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q2 2023 Ardelyx Inc Earnings Release Q2 2023 Ardelyx Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q3 2023 Ardelyx Inc Earnings Release Q3 2023 Ardelyx Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 52.158 | 10.097 | 7.571 | 5.281 | 2.607 |
| Ingresos | 52.158 | 10.097 | 7.571 | 5.281 | 2.607 |
| Gastos totales de explotación | 115.917 | 164.443 | 98.351 | 96.544 | 93.554 |
| Gastos de venta/general/administración Gastos, total | 76.599 | 68.803 | 33.153 | 24.267 | 23.715 |
| Investigación y desarrollo | 35.201 | 88.44 | 65.053 | 71.677 | 69.373 |
| Ingresos de explotación | -63.759 | -154.346 | -90.78 | -91.263 | -90.947 |
| Otros, netos | -0.04 | 0.687 | 1.568 | 2.41256 | 127.381 |
| Ingresos netos antes de impuestos | -67.199 | -158.161 | -94.311 | -94.637 | -91.294 |
| Ingresos netos después de impuestos | -67.207 | -158.165 | -94.313 | -94.94 | -91.298 |
| Beneficio neto antes de partidas extra. Elementos | -67.207 | -158.165 | -94.313 | -94.94 | -91.298 |
| Ingresos netos | -67.207 | -158.165 | -94.313 | -94.94 | -91.298 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -67.207 | -158.165 | -94.313 | -94.94 | -91.298 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -67.207 | -158.165 | -94.313 | -94.94 | -91.298 |
| Beneficio neto diluido | -67.207 | -158.165 | -94.313 | -94.94 | -91.298 |
| Promedio ponderado de acciones diluidas | 158.69 | 104.206 | 89.5821 | 64.4781 | 56.2199 |
| BPA diluido sin partidas extraordinarias | -0.42351 | -1.51782 | -1.05281 | -1.47244 | -1.62394 |
| Dividends per Share - Common Stock Primary Issue | |||||
| BPA normalizado diluido | -0.42351 | -1.47914 | -1.05281 | -1.47244 | -1.62394 |
| Coste de los ingresos, total | 4.117 | 1 | 0.145 | 0.6 | 0.466 |
| Beneficio bruto | 48.041 | 9.097 | 7.426 | 4.681 | 2.141 |
| Total de partidas extraordinarias | |||||
| Ingresos por intereses (gastos), netos No operativos | -3.4 | -4.502 | -5.099 | -5.78656 | -127.728 |
| Gastos (ingresos) extraordinarios | 6.2 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 11.369 | 44.178 | 4.986 | 2.526 | 0.468 |
| Ingresos | 11.369 | 44.178 | 4.986 | 2.526 | 0.468 |
| Coste de los ingresos, total | 1.537 | 3.162 | 0.732 | 0.138 | 0.085 |
| Beneficio bruto | 9.832 | 41.016 | 4.254 | 2.388 | 0.383 |
| Gastos totales de explotación | 37.433 | 32.035 | 26.866 | 28.741 | 28.275 |
| Gastos de venta/general/administración Gastos, total | 26.803 | 19.731 | 18.667 | 18.862 | 19.339 |
| Investigación y desarrollo | 9.093 | 9.142 | 7.467 | 9.741 | 8.851 |
| Ingresos de explotación | -26.064 | 12.143 | -21.88 | -26.215 | -27.807 |
| Ingresos por intereses (gastos), netos No operativos | -1.028 | -0.991 | -0.886 | -0.787 | -0.746 |
| Otros, netos | 0.333 | -0.457 | -0.127 | 0.07 | 0.484 |
| Ingresos netos antes de impuestos | -26.759 | 10.695 | -22.893 | -26.932 | -28.069 |
| Ingresos netos después de impuestos | -26.773 | 10.695 | -22.893 | -26.938 | -28.071 |
| Beneficio neto antes de partidas extra. Elementos | -26.773 | 10.695 | -22.893 | -26.938 | -28.071 |
| Ingresos netos | -26.773 | 10.695 | -22.893 | -26.938 | -28.071 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -26.773 | 10.695 | -22.893 | -26.938 | -28.071 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -26.773 | 10.695 | -22.893 | -26.938 | -28.071 |
| Beneficio neto diluido | -26.773 | 10.695 | -22.893 | -26.938 | -28.071 |
| Promedio ponderado de acciones diluidas | 207.023 | 192.801 | 165.105 | 145.544 | 130.935 |
| BPA diluido sin partidas extraordinarias | -0.12932 | 0.05547 | -0.13866 | -0.18508 | -0.21439 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.12807 | 0.05547 | -0.13866 | -0.18508 | -0.21439 |
| Gastos (ingresos) extraordinarios |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 153.603 | 133.649 | 194.686 | 252.062 | 176.371 |
| Efectivo e inversiones a corto plazo | 123.909 | 116.689 | 186.484 | 247.512 | 168.089 |
| Efectivo y Equivalentes | 84.313 | 71.175 | 91.032 | 181.133 | 78.768 |
| Inversiones a corto plazo | 27.769 | 44.261 | 95.452 | 66.379 | 89.321 |
| Prepaid Expenses | 18.679 | 16.458 | 8.202 | 3.8 | 3.197 |
| Total Assets | 190.066 | 149.913 | 201.562 | 259.782 | 183.332 |
| Property/Plant/Equipment, Total - Net | 10.518 | 15.114 | 4.21 | 7.406 | 5.611 |
| Property/Plant/Equipment, Total - Gross | 20.175 | 31.005 | 18.66 | 20.032 | 15.803 |
| Accumulated Depreciation, Total | -9.657 | -15.891 | -14.45 | -12.626 | -10.192 |
| Other Long Term Assets, Total | 25.945 | 1.15 | 0.552 | 0.314 | 1.35 |
| Total Current Liabilities | 65.603 | 52.821 | 28.416 | 22.22 | 17.728 |
| Accounts Payable | 10.859 | 4.277 | 5.626 | 2.187 | 1.148 |
| Accrued Expenses | 21.281 | 14.977 | 12.785 | 12.591 | 14.596 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 6.752 | 1.303 | 5.838 | 6.259 | 1.984 |
| Total Liabilities | 91.737 | 67.296 | 75.45 | 73.127 | 67.519 |
| Total Long Term Debt | 0 | 0 | 46.621 | 48.831 | 49.209 |
| Other Liabilities, Total | 26.134 | 14.475 | 0.413 | 2.076 | 0.582 |
| Total Equity | 98.329 | 82.617 | 126.112 | 186.655 | 115.813 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.02 | 0.013 | 0.009 | 0.009 | 0.006 |
| Additional Paid-In Capital | 878.5 | 795.54 | 680.872 | 647.078 | 481.357 |
| Retained Earnings (Accumulated Deficit) | -780.137 | -712.93 | -554.765 | -460.452 | -365.512 |
| Other Equity, Total | -0.054 | -0.006 | -0.004 | 0.02 | -0.038 |
| Total Liabilities & Shareholders’ Equity | 190.066 | 149.913 | 201.562 | 259.782 | 183.332 |
| Total Common Shares Outstanding | 198.575 | 130.183 | 93.6 | 88.8177 | 62.5166 |
| Total deudores, neto | 7.733 | 0.502 | 0 | 0.75 | 5.085 |
| Accounts Receivable - Trade, Net | 7.733 | 0.502 | 0 | 0.75 | 5.085 |
| Long Term Debt | 0 | 46.621 | 48.831 | 49.209 | |
| Current Port. of LT Debt/Capital Leases | 26.711 | 32.264 | 4.167 | 1.183 | |
| Long Term Investments | 0 | 2.114 | |||
| Cash | 11.827 | 1.253 | |||
| Total Inventory | 3.282 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 167.047 | 153.603 | 119.875 | 114.107 | 114.225 |
| Efectivo e inversiones a corto plazo | 130.373 | 123.909 | 90.623 | 81.012 | 89.704 |
| Efectivo y Equivalentes | 84.501 | 84.313 | 60.976 | 50.433 | 39.522 |
| Inversiones a corto plazo | 37.886 | 27.769 | 28.995 | 27.604 | 42.627 |
| Total deudores, neto | 12.12 | 7.733 | 5.208 | 5.623 | 4.394 |
| Accounts Receivable - Trade, Net | 12.12 | 7.733 | 5.208 | 5.623 | 4.394 |
| Prepaid Expenses | 19.731 | 18.679 | 22.794 | 22.943 | 16.64 |
| Total Assets | 217.019 | 190.066 | 144.672 | 131.61 | 129.408 |
| Property/Plant/Equipment, Total - Net | 9.074 | 10.518 | 11.476 | 12.595 | 13.955 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 40.898 | 25.945 | 13.321 | 4.908 | 1.228 |
| Total Current Liabilities | 63.063 | 65.603 | 51.951 | 48.699 | 47.843 |
| Accounts Payable | 10.513 | 10.859 | 3.113 | 4.294 | 5.03 |
| Accrued Expenses | 20.125 | 21.281 | 18.294 | 18.032 | 16.674 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 26.88 | 26.711 | 26.541 | 26.373 | 26.139 |
| Other Current Liabilities, Total | 5.545 | 6.752 | 4.003 | ||
| Total Liabilities | 91.598 | 91.737 | 77.811 | 78.568 | 65.218 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Other Liabilities, Total | 28.535 | 26.134 | 25.86 | 29.869 | 17.375 |
| Total Equity | 125.421 | 98.329 | 66.861 | 53.042 | 64.19 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.021 | 0.02 | 0.019 | 0.015 | 0.014 |
| Additional Paid-In Capital | 932.33 | 878.5 | 857.788 | 821.075 | 805.265 |
| Retained Earnings (Accumulated Deficit) | -806.91 | -780.137 | -790.832 | -767.939 | -741.001 |
| Other Equity, Total | -0.02 | -0.054 | -0.114 | -0.109 | -0.088 |
| Total Liabilities & Shareholders’ Equity | 217.019 | 190.066 | 144.672 | 131.61 | 129.408 |
| Total Common Shares Outstanding | 214.462 | 198.575 | 187.4 | 153.798 | 136.33 |
| Cash | 7.986 | 11.827 | 0.652 | 2.975 | 7.555 |
| Total Inventory | 4.823 | 3.282 | 1.25 | 4.529 | 3.487 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -67.207 | -158.165 | -94.313 | -94.94 | -91.298 |
| Efectivo de actividades de explotación | -70.044 | -152.551 | -81.435 | -76.484 | -70.274 |
| Efectivo de actividades de explotación | 1.144 | 1.441 | 1.824 | 2.501 | 2.678 |
| Partidas no monetarias | 15.594 | 16.095 | 14.267 | 12.97 | 8.993 |
| Cash Taxes Paid | 0.006 | 0.004 | 0.001 | 0.002 | 0.004 |
| Cambios en el capital circulante | -19.575 | -11.922 | -3.213 | 2.985 | 9.353 |
| Efectivo de actividades de inversión | 18.415 | 50.948 | -31.442 | 23.373 | -29.894 |
| Gastos de capital | -0.055 | -1.867 | -0.324 | -0.325 | -0.311 |
| Otras partidas de flujo de caja de inversión, total | 18.47 | 52.815 | -31.118 | 23.698 | -29.583 |
| Efectivo procedente de actividades de financiación | 75.341 | 82.999 | 22.776 | 155.476 | 103.553 |
| Elementos de flujo de caja de financiación | 9.581 | -0.106 | |||
| Emisión (retiro) de acciones, neto | 71.827 | 102.549 | 22.901 | 155.476 | 54.261 |
| Variación neta de la tesorería | 23.712 | -18.604 | -90.101 | 102.365 | 3.385 |
| Emisión (amortización) de deuda, neta | -6.067 | -19.444 | -0.125 | 0 | 49.292 |
| Intereses pagados en efectivo | 2.901 | 3.469 | 4.2 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -26.773 | -67.207 | -77.902 | -55.009 | -28.071 |
| Cash From Operating Activities | -44.795 | -70.044 | -84.328 | -58.901 | -27.62 |
| Cash From Operating Activities | 1.144 | 1.035 | 0.407 | 0.232 | |
| Non-Cash Items | 5.354 | 15.594 | 11.345 | 8.439 | 4.311 |
| Cash Taxes Paid | 0 | 0.006 | 0.006 | 0.006 | -0.001 |
| Cash Interest Paid | 0.86 | 2.901 | 2.079 | 1.36 | 0.741 |
| Changes in Working Capital | -23.376 | -19.575 | -18.806 | -12.738 | -4.092 |
| Cash From Investing Activities | -9.777 | 18.415 | 16.974 | 17.806 | 2.332 |
| Capital Expenditures | -0.014 | -0.055 | 0 | 0 | 0 |
| Other Investing Cash Flow Items, Total | -9.763 | 18.47 | 16.974 | 17.806 | 2.332 |
| Cash From Financing Activities | 50.919 | 75.341 | 56.554 | 22.075 | -0.063 |
| Issuance (Retirement) of Stock, Net | 50.919 | 71.827 | 53.04 | 18.561 | 6.004 |
| Net Change in Cash | -3.653 | 23.712 | -10.8 | -19.02 | -25.351 |
| Financing Cash Flow Items | 9.581 | 9.581 | 9.581 | ||
| Issuance (Retirement) of Debt, Net | 0 | -6.067 | -6.067 | -6.067 | -6.067 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 10.3102 | 22111601 | 2337268 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 7.0889 | 15203116 | 14549803 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 5.1382 | 11019607 | 857562 | 2023-03-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.0273 | 8637108 | 323595 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 2.0975 | 4498307 | 2130032 | 2023-03-31 | HIGH |
| Susquehanna International Group, LLP | Investment Advisor | 1.9236 | 4125297 | 2705598 | 2023-03-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.5949 | 3420408 | 809464 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.4631 | 3137693 | 2688000 | 2023-03-31 | HIGH |
| T. Rowe Price Associates, Inc. | Investment Advisor | 1.1945 | 2561796 | 265370 | 2023-03-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 0.9559 | 2050000 | 400000 | 2023-03-31 | MED |
| Lion Point Capital, L.P. | Hedge Fund | 0.9497 | 2036667 | 151667 | 2023-03-31 | MED |
| BofA Global Research (US) | Research Firm | 0.9418 | 2019727 | 1901741 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9224 | 1978173 | 251236 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 0.7929 | 1700423 | 221276 | 2023-03-31 | HIGH |
| Goldman Sachs & Company, Inc. | Research Firm | 0.7639 | 1638312 | 1266327 | 2023-03-31 | MED |
| Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 0.7219 | 1548132 | 1548132 | 2023-03-31 | MED |
| Knott Partners Management, LLC | Hedge Fund | 0.6994 | 1500000 | 0 | 2023-03-31 | LOW |
| Coho Partners, Ltd. | Investment Advisor | 0.6239 | 1338009 | -1028831 | 2023-01-31 | LOW |
| Citi Investment Research (US) | Research Firm | 0.6009 | 1288797 | 1235054 | 2023-03-31 | MED |
| Pekin Hardy Strauss Wealth Management | Investment Advisor | 0.5791 | 1241872 | -427876 | 2023-03-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Ardelyx, Inc. Company profile
Sobre Ardelyx Inc
Ardelyx, Inc. es una empresa biofarmacéutica. La empresa se centra en el descubrimiento, el desarrollo y la comercialización de medicamentos avanzados que satisfacen importantes necesidades médicas no cubiertas. La cartera de productos de la empresa incluye IBSRELA (tenapanor), XPHOZAH, el programa RDX013 y el programa RDX020. Tenapanor es una terapia de moléculas pequeñas en desarrollo para el tratamiento de la hiperfosfatemia, una condición de niveles elevados de fosfato en la sangre, común entre los pacientes con enfermedad renal crónica (ERC) en diálisis. Tenapanor tiene un mecanismo de acción y actúa localmente en el intestino para inhibir el intercambiador de hidrógeno de sodio 3 (NHE3). IBSRELA se ha desarrollado para el tratamiento de pacientes con síndrome del intestino irritable con estreñimiento (SII-C). XPHOZAH es un medicamento para el control del fósforo sérico en pacientes adultos con ERC en diálisis. Programa RDX013 es una pequeña molécula secretagoga de potasio para el tratamiento de la hiperpotasemia. RDX020 Program es una pequeña molécula para el tratamiento de la acidosis metabólica.
El precio actual de la acción Ardelyx, Inc. en tiempo real es 3.97 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: MaxLinear, Inc., Limoneira, Adams Resources & Energy, Mosaic, Electrameccanica Vehicles Corp. y Kingfisher PLC. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Bio Therapeutic Drugs |
34175 Ardenwood Blvd
FREMONT
CALIFORNIA 94555
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com